Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17255526 | INFLUENZA VIRUS HEMAGGLUTININ MUTANTS | December 2020 | May 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17252210 | INTEGRATED MANUFACTURING AND CHROMATOGRAPHIC SYSTEM FOR VIRUS PRODUCTION | December 2020 | April 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17110585 | COATED EGG YOLK CORES, METHODS OF MAKING AND METHODS OF USE THEREOF | December 2020 | June 2022 | Allow | 19 | 1 | 1 | No | No |
| 17054308 | VECTORS FOR DNA VACCINATION | November 2020 | March 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17082865 | MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF | October 2020 | July 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 17050602 | NOVEL SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS | October 2020 | April 2023 | Allow | 29 | 2 | 1 | Yes | No |
| 17050188 | PREPARATION AND USE OF MITOCHONDRION-TARGETING SELF-ASSEMBLED PROTEIN NANOPARTICLE | October 2020 | February 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17067257 | Methods and Devices for Real-Time Diagnostic Testing (RDT) for Ebola and other Infectious Diseases | October 2020 | December 2022 | Abandon | 27 | 1 | 1 | No | No |
| 17063706 | HERPES 1 ANTIBODY SYSTEM | October 2020 | September 2023 | Abandon | 35 | 2 | 1 | Yes | No |
| 17063715 | HERPES 2 ANTIBODY SYSTEM | October 2020 | September 2023 | Abandon | 35 | 2 | 1 | No | No |
| 17039557 | HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN | September 2020 | August 2022 | Allow | 22 | 2 | 1 | Yes | No |
| 17035480 | METHODS FOR PURIFICATION OF RECOMBINANT AAV VECTORS | September 2020 | August 2023 | Allow | 34 | 2 | 1 | No | No |
| 17021286 | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | September 2020 | January 2021 | Allow | 4 | 1 | 0 | No | No |
| 16980838 | MULTIVALENT LIVE INFLUENZA VACCINE PLATFORM USING RECOMBINANT ADENOVIRUS | September 2020 | February 2023 | Allow | 29 | 2 | 1 | Yes | No |
| 17013000 | INFLUENZA PEPTIDES AND COMPOSITIONS | September 2020 | May 2022 | Allow | 20 | 1 | 1 | No | No |
| 17011140 | MULTIPLE MOSQUITO-BORNE FLAVIVIRUS VACCINE AND USE THEREOF IN INDUCING NEUTRALIZING ANTIBODIES | September 2020 | November 2022 | Abandon | 26 | 1 | 1 | No | No |
| 17011934 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF | September 2020 | April 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17004818 | Filovirus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same | August 2020 | March 2023 | Allow | 31 | 2 | 1 | No | No |
| 16975846 | Multivalent Live-attenuated Influenza Vaccine for Prevention and Control of Equine Influenza Virus (EIV) in Horses | August 2020 | September 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 17002064 | SIMIAN (GORILLA) ADENOVIRUS OR ADENOVIRAL VECTORS AND METHODS OF USE | August 2020 | March 2022 | Allow | 19 | 1 | 0 | No | No |
| 16959117 | A UNIVERSAL VACCINE AGAINST INFLUENZA | August 2020 | April 2022 | Abandon | 22 | 0 | 1 | No | No |
| 16998548 | SCALABLE PRODUCTION METHOD FOR AAV | August 2020 | March 2022 | Allow | 19 | 2 | 0 | No | No |
| 16996297 | ANTI-SARS-COV-2-SPIKE GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | August 2020 | January 2021 | Allow | 5 | 1 | 0 | No | No |
| 16987049 | SARS-CoV-2 IgG/IgM ANTI-BODY DETECTION KIT | August 2020 | September 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16984827 | METHOD OF TREATING INFLUENZA A | August 2020 | September 2022 | Allow | 25 | 2 | 1 | No | No |
| 16958170 | OPTIMIZED HOST/VECTOR SYSTEM FOR PRODUCING PROTECTIVE MONO- AND MULTIVALENT SUBUNIT VACCINES ON THE BASIS OF THE YEAST KLUYVEROMYCES LACTIS | June 2020 | October 2023 | Allow | 39 | 3 | 1 | No | No |
| 16912678 | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | June 2020 | July 2020 | Allow | 1 | 0 | 0 | Yes | No |
| 16901705 | VIRUS-LIKE PARTICLES CO-EXPRESSING TOXOPLASMA GONDII IMC, ROP18, AND MIC8, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | June 2020 | August 2022 | Allow | 26 | 1 | 1 | No | No |
| 16898268 | CHIKV RNA VACCINES | June 2020 | February 2022 | Allow | 20 | 2 | 1 | No | No |
| 16894291 | PARENTERAL NOROVIRUS VACCINE FORMULATIONS | June 2020 | February 2023 | Allow | 33 | 2 | 1 | No | No |
| 16946092 | BINDING MOLECULES DIRECTED AGAINST INFLUENZA HEMAGGLUTININ AND USES THEREOF | June 2020 | March 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 16770190 | VACCINE COMPOSITION FOR CLASSICAL SWINE FEVER AND PREPARATION METHOD THEREOF | June 2020 | August 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16769974 | REPLICATION-LIMITED MUCOSAL IMMUNE VACCINE FOR INFLUENZA VIRUS | June 2020 | January 2023 | Abandon | 32 | 2 | 1 | No | No |
| 16768547 | GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS IIIB | May 2020 | December 2022 | Allow | 31 | 1 | 0 | No | No |
| 16767060 | METHOD OF TREATMENT | May 2020 | January 2024 | Allow | 44 | 2 | 1 | No | No |
| 16766048 | H7 Avian Influenza Vaccine Strain which Differentiates Infected from Vaccinated Animals, Preparation Method Therefor, and Application | May 2020 | August 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 15733120 | H9 AVIAN INFLUENZA VACCINE STRAIN WHICH DIFFERENTIATES INFECTED FROM VACCINATED ANIMALS, AND PREPARATION METHOD THEREFOR | May 2020 | September 2022 | Allow | 28 | 3 | 1 | No | No |
| 16765758 | ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND USE FOR INHIBITING ANGIOGENESIS | May 2020 | May 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 15931939 | MOLECULES THAT BIND TO SARS-CoV-2 | May 2020 | September 2020 | Allow | 4 | 1 | 0 | Yes | No |
| 16870669 | HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ | May 2020 | May 2022 | Allow | 24 | 3 | 1 | Yes | No |
| 16865107 | RABIES VACCINE | May 2020 | February 2022 | Allow | 21 | 1 | 1 | No | No |
| 16863705 | SINGLE CYCLE REPLICATING ADENOVIRUS VECTORS | April 2020 | November 2021 | Allow | 19 | 1 | 1 | No | No |
| 16758932 | A POLYGENE INFLUENZA VACCINE | April 2020 | March 2022 | Allow | 23 | 0 | 1 | Yes | No |
| 16853973 | CHIKUNGUNYA VIRUS RNA VACCINES | April 2020 | August 2021 | Allow | 16 | 1 | 1 | No | No |
| 16756973 | MUTANT OF HEMAGGLUTININ PROTEIN OF H3N2 SUBTYPE INFLUENZA VIRUS AND USE THEREOF | April 2020 | June 2022 | Allow | 26 | 2 | 1 | No | No |
| 16756740 | METHODS AND COMPOSITIONS FOR NOROVIRUS VACCINES AND DIAGNOSTICS | April 2020 | September 2022 | Allow | 29 | 1 | 1 | No | No |
| 16850519 | ZIKA VIRUS RNA VACCINES | April 2020 | November 2021 | Allow | 19 | 1 | 1 | No | No |
| 16756054 | AAV VECTORS | April 2020 | March 2024 | Allow | 47 | 2 | 1 | No | No |
| 16848564 | METHOD TO IMPROVE VIRUS FILTRATION CAPACITY | April 2020 | September 2021 | Allow | 17 | 1 | 1 | No | No |
| 16848318 | ZIKA VIRUS MRNA VACCINES | April 2020 | August 2021 | Allow | 16 | 1 | 1 | Yes | No |
| 16847360 | ORF7 DEFICIENT VARICELLA VIRUS, VACCINE COMPRISING THE VIRUS AND USE THEREOF | April 2020 | August 2021 | Allow | 16 | 1 | 0 | No | No |
| 16840723 | BROAD AND LONG-LASTING INFLUENZA VACCINE | April 2020 | June 2023 | Abandon | 39 | 4 | 1 | No | No |
| 16753364 | LIVE-ATTENUATED FLAVIRUSES WITH HETEROLOGOUS ANTIGENS | April 2020 | February 2023 | Allow | 34 | 2 | 1 | No | No |
| 16651435 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS | March 2020 | September 2021 | Allow | 18 | 1 | 1 | Yes | No |
| 16831525 | METHODS FOR DETECTION OF FLAVIVIRUS ANTIBODIES | March 2020 | February 2022 | Allow | 22 | 1 | 1 | No | No |
| 16645067 | METHODS AND COMPOSITIONS FOR PREVENTING INFLUENZA INFECTION | March 2020 | July 2022 | Allow | 28 | 1 | 1 | No | No |
| 16809268 | METHODS FOR PREVENTING DENGUE AND HEPATITIS A | March 2020 | April 2022 | Allow | 25 | 2 | 1 | No | No |
| 16644123 | MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF ZIKA VIRUS | March 2020 | April 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16796350 | VACCINIA VIRAL VECTORS ENCODING CHIMERIC VIRUS LIKE PARTICLES | February 2020 | April 2022 | Allow | 26 | 2 | 1 | No | No |
| 16640483 | PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA | February 2020 | April 2023 | Allow | 38 | 2 | 1 | Yes | No |
| 16639302 | Vaccine Adjuvant Comprising Lipopeptide-Inserted Liposome as Effective Ingredient and Use Thereof | February 2020 | November 2022 | Allow | 33 | 2 | 1 | Yes | No |
| 16781781 | COMBINATION VACCINE | February 2020 | October 2021 | Allow | 21 | 1 | 1 | Yes | No |
| 16635240 | HEPATITIS B NANOPARTICLE-BASED VACCINE FOR INFLUENZA VIRUS | January 2020 | September 2022 | Allow | 31 | 2 | 1 | No | No |
| 16630951 | LYSSAVIRUS ANTIGEN CONSTRUCTS | January 2020 | November 2021 | Allow | 22 | 2 | 1 | No | No |
| 16629525 | SENECAVIRUS A IMMUNOGENIC COMPOSITIONS AND METHODS THEREOF | January 2020 | August 2021 | Allow | 20 | 2 | 1 | Yes | No |
| 16628228 | METHOD FOR PREPARING INFLUENZA WORKING VIRUS SEED STOCK, METHOD FOR PREPARING INFLUENZA VACCINE USING SAME SEED STOCK, AND VIRUS SEED STOCK PREPARED BY SAME METHOD | January 2020 | September 2023 | Allow | 44 | 4 | 1 | Yes | No |
| 16722437 | INFLUENZA VACCINE | December 2019 | September 2022 | Allow | 33 | 3 | 1 | Yes | No |
| 16711184 | VIRAL VECTOR MANUFACTURE | December 2019 | August 2021 | Abandon | 20 | 1 | 1 | No | No |
| 16694748 | INFLUENZA VIRUSES WITH MUTANT PB2 GENE SEGMENT AS LIVE ATTENUATED VACCINES | November 2019 | March 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16616416 | ANTI-DENGUE VIRUS ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USES THEREOF | November 2019 | July 2021 | Allow | 20 | 2 | 0 | No | No |
| 16615350 | METHODS AND COMPOSITIONS FOR DENGUE VIRUS SEROTYPE 4 EPITOPES | November 2019 | October 2021 | Allow | 23 | 1 | 1 | No | No |
| 16680402 | SELECTIVE RECOVERY | November 2019 | May 2021 | Allow | 18 | 1 | 1 | No | No |
| 16611512 | GENE THERAPY FOR CEROID LIPOFUSCINOSES | November 2019 | September 2022 | Allow | 35 | 0 | 1 | Yes | No |
| 16610660 | Bovine Respiratory Disease Vaccine | November 2019 | June 2022 | Allow | 31 | 1 | 1 | No | No |
| 16666572 | METHODS OF TREATING EARLY RHEUMATOID ARTHRITIS | October 2019 | July 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16665104 | INFLUENZA VIRUS REASSORTMENT | October 2019 | May 2021 | Abandon | 19 | 1 | 1 | No | No |
| 16664199 | COMPOSITIONS AND METHODS FOR DETECTING HUMAN PEGIVIRUS 2 (HPgV-2) | October 2019 | December 2020 | Abandon | 14 | 0 | 1 | No | No |
| 16663261 | HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN | October 2019 | June 2020 | Allow | 8 | 1 | 0 | No | No |
| 16662784 | METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINES | October 2019 | October 2021 | Allow | 24 | 1 | 1 | Yes | No |
| 16605696 | METHODS TO REDUCE THE LIKELIHOOD OF MATERNAL AND FETAL ZIKA VIRUS DISEASE | October 2019 | March 2021 | Abandon | 17 | 0 | 1 | No | No |
| 16653229 | ANTIBODY-MEDIATED NEUTRALIZATION OF MARBURG VIRUS | October 2019 | March 2021 | Allow | 17 | 1 | 1 | Yes | No |
| 16597850 | EPITOPE-SUBSTITUTED VACCINE FOR USE IN IMPROVING SAFETY AND IMMUNOGENICITY AGAINST DENGUE VIRUSES | October 2019 | May 2021 | Allow | 19 | 1 | 1 | No | No |
| 16596039 | NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | October 2019 | July 2021 | Allow | 21 | 1 | 1 | Yes | No |
| 16499355 | PROTEIN PURIFICATION METHOD AND KIT | September 2019 | March 2024 | Allow | 54 | 3 | 1 | No | No |
| 16583390 | INFLUENZA VIRUS REASSORTMENT | September 2019 | February 2021 | Abandon | 17 | 0 | 1 | No | No |
| 16496049 | DEVELOPMENT OF AN ALTERNATIVE MODIFIED LIVE INFLUENZA B VIRUS VACCINE | September 2019 | September 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16495624 | ANTIBODIES TO ANDES HANTAVIRUS, AND METHODS FOR USING SAME | September 2019 | February 2022 | Allow | 29 | 2 | 1 | Yes | Yes |
| 16571550 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | September 2019 | May 2021 | Allow | 20 | 2 | 1 | Yes | No |
| 16570535 | SINGLE CYCLE REPLICATING ADENOVIRUS VECTORS | September 2019 | March 2020 | Allow | 6 | 2 | 0 | No | No |
| 16493441 | GENOME-WIDE IDENTIFICATION OF IMMUNE EVASION FUNCTIONS IN A VIRUS | September 2019 | October 2023 | Allow | 49 | 2 | 1 | Yes | No |
| 16561953 | DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF | September 2019 | July 2022 | Allow | 34 | 3 | 1 | Yes | No |
| 16557177 | NOVEL PORCINE PARAINFLUENZA VIRUS TYPE 1 ISOLATES AND IMMUNOGENIC COMPOSITIONS THEREFROM | August 2019 | April 2021 | Allow | 19 | 1 | 1 | Yes | No |
| 16554133 | Altering the Immundominance Hierarchy Using a DNA Vaccine Expressing Conserved Regions | August 2019 | July 2021 | Allow | 22 | 1 | 1 | No | No |
| 16487674 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR | August 2019 | July 2023 | Allow | 47 | 1 | 1 | Yes | No |
| 16547262 | GENERATION OF INFECTIOUS INFLUENZA VIRUSES FROM VIRUS-LIKE PARTICLES | August 2019 | July 2021 | Allow | 23 | 1 | 1 | No | No |
| 16541182 | AUTOMATED BIOLOGICAL SAMPLE COLLECTION SYSTEM AND METHODS | August 2019 | December 2020 | Allow | 16 | 2 | 1 | No | No |
| 16540811 | Influenza Peptides and Compositions | August 2019 | October 2020 | Abandon | 14 | 2 | 0 | Yes | No |
| 16532728 | LIPIDS AS SYNTHETIC VECTORS TO ENHANCE ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY | August 2019 | January 2023 | Allow | 42 | 4 | 1 | Yes | No |
| 16527836 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF | July 2019 | September 2020 | Allow | 13 | 2 | 0 | No | No |
| 16480727 | HEMAGGLUTININ-SPECIFIC ANTIBODIES AND USES THEREOF | July 2019 | September 2022 | Allow | 38 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BLUMEL, BENJAMIN P.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BLUMEL, BENJAMIN P works in Art Unit 1648 and has examined 863 patent applications in our dataset. With an allowance rate of 62.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner BLUMEL, BENJAMIN P's allowance rate of 62.0% places them in the 24% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BLUMEL, BENJAMIN P receive 2.22 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BLUMEL, BENJAMIN P is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +43.8% benefit to allowance rate for applications examined by BLUMEL, BENJAMIN P. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.8% of applications are subsequently allowed. This success rate is in the 36% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 44.9% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 140.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 88% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 78.4% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 82.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 75.6% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 4.5% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.7% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.